Logo image of ILMN

ILLUMINA INC (ILMN) Stock Fundamental Analysis

NASDAQ:ILMN - Nasdaq - US4523271090 - Common Stock - Currency: USD

71.1  -0.1 (-0.14%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ILMN. ILMN was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ILMN get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on ILMN.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ILMN had positive earnings in the past year.
ILMN had a positive operating cash flow in the past year.
In multiple years ILMN reported negative net income over the last 5 years.
ILMN had a positive operating cash flow in each of the past 5 years.
ILMN Yearly Net Income VS EBIT VS OCF VS FCFILMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B -3B -4B

1.2 Ratios

ILMN has a worse Return On Assets (-19.39%) than 60.00% of its industry peers.
ILMN's Return On Equity of -51.50% is on the low side compared to the rest of the industry. ILMN is outperformed by 70.91% of its industry peers.
ILMN has a Return On Invested Capital of 10.73%. This is amongst the best in the industry. ILMN outperforms 87.27% of its industry peers.
Industry RankSector Rank
ROA -19.39%
ROE -51.5%
ROIC 10.73%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ILMN Yearly ROA, ROE, ROICILMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

Looking at the Operating Margin, with a value of 14.78%, ILMN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
In the last couple of years the Operating Margin of ILMN has declined.
Looking at the Gross Margin, with a value of 65.44%, ILMN belongs to the top of the industry, outperforming 92.73% of the companies in the same industry.
ILMN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.78%
PM (TTM) N/A
GM 65.44%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
ILMN Yearly Profit, Operating, Gross MarginsILMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

ILMN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ILMN has about the same amount of shares outstanding.
The number of shares outstanding for ILMN has been increased compared to 5 years ago.
ILMN has a worse debt/assets ratio than last year.
ILMN Yearly Shares OutstandingILMN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ILMN Yearly Total Debt VS Total AssetsILMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ILMN has an Altman-Z score of 2.70. This is not the best score and indicates that ILMN is in the grey zone with still only limited risk for bankruptcy at the moment.
ILMN has a Altman-Z score of 2.70. This is in the better half of the industry: ILMN outperforms 67.27% of its industry peers.
ILMN has a debt to FCF ratio of 2.81. This is a good value and a sign of high solvency as ILMN would need 2.81 years to pay back of all of its debts.
ILMN's Debt to FCF ratio of 2.81 is amongst the best of the industry. ILMN outperforms 81.82% of its industry peers.
ILMN has a Debt/Equity ratio of 0.63. This is a neutral value indicating ILMN is somewhat dependend on debt financing.
ILMN's Debt to Equity ratio of 0.63 is on the low side compared to the rest of the industry. ILMN is outperformed by 69.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.81
Altman-Z 2.7
ROIC/WACC1.05
WACC10.24%
ILMN Yearly LT Debt VS Equity VS FCFILMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 1.78 indicates that ILMN should not have too much problems paying its short term obligations.
ILMN has a worse Current ratio (1.78) than 67.27% of its industry peers.
ILMN has a Quick Ratio of 1.42. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.42, ILMN is not doing good in the industry: 65.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.42
ILMN Yearly Current Assets VS Current LiabilitesILMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

5

3. Growth

3.1 Past

ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 181.61%, which is quite impressive.
The earnings per share for ILMN have been decreasing by -17.93% on average. This is quite bad
ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.93%.
Measured over the past years, ILMN shows a small growth in Revenue. The Revenue has been growing by 4.29% on average per year.
EPS 1Y (TTM)181.61%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%514.29%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-1.6%

3.2 Future

The Earnings Per Share is expected to grow by 23.52% on average over the next years. This is a very strong growth
ILMN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.80% yearly.
EPS Next Y85.5%
EPS Next 2Y44.89%
EPS Next 3Y33.17%
EPS Next 5Y23.52%
Revenue Next Year-0.75%
Revenue Next 2Y1.94%
Revenue Next 3Y3.41%
Revenue Next 5Y4.8%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ILMN Yearly Revenue VS EstimatesILMN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B
ILMN Yearly EPS VS EstimatesILMN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

ILMN is valuated quite expensively with a Price/Earnings ratio of 29.02.
63.64% of the companies in the same industry are more expensive than ILMN, based on the Price/Earnings ratio.
ILMN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.29, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 15.64, which indicates a correct valuation of ILMN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ILMN indicates a rather cheap valuation: ILMN is cheaper than 85.45% of the companies listed in the same industry.
ILMN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.32.
Industry RankSector Rank
PE 29.02
Fwd PE 15.64
ILMN Price Earnings VS Forward Price EarningsILMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ILMN is valued cheaper than 92.73% of the companies in the same industry.
87.27% of the companies in the same industry are more expensive than ILMN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.87
EV/EBITDA 11.94
ILMN Per share dataILMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

ILMN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ILMN's earnings are expected to grow with 33.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y44.89%
EPS Next 3Y33.17%

More info and screens

0

5. Dividend

5.1 Amount

ILMN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ILLUMINA INC

NASDAQ:ILMN (4/21/2025, 1:59:09 PM)

71.1

-0.1 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-06 2025-02-06/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners104.43%
Inst Owner Change0.67%
Ins Owners0.14%
Ins Owner Change4.08%
Market Cap11.25B
Analysts73.55
Price Target131.54 (85.01%)
Short Float %4.13%
Short Ratio2.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.56%
Min EPS beat(2)-7.76%
Max EPS beat(2)26.88%
EPS beat(4)2
Avg EPS beat(4)19.35%
Min EPS beat(4)-60.91%
Max EPS beat(4)119.22%
EPS beat(8)6
Avg EPS beat(8)340.29%
EPS beat(12)9
Avg EPS beat(12)230.8%
EPS beat(16)13
Avg EPS beat(16)182.05%
Revenue beat(2)0
Avg Revenue beat(2)-1.04%
Min Revenue beat(2)-1.91%
Max Revenue beat(2)-0.18%
Revenue beat(4)2
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-1.91%
Max Revenue beat(4)0.91%
Revenue beat(8)4
Avg Revenue beat(8)-0.46%
Revenue beat(12)4
Avg Revenue beat(12)-1.2%
Revenue beat(16)8
Avg Revenue beat(16)0.55%
PT rev (1m)-9.76%
PT rev (3m)-20.78%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-5.96%
EPS NY rev (1m)-1.49%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-4.63%
Revenue NY rev (1m)-1.37%
Revenue NY rev (3m)-4.22%
Valuation
Industry RankSector Rank
PE 29.02
Fwd PE 15.64
P/S 2.57
P/FCF 15.87
P/OCF 13.44
P/B 4.74
P/tB 11.66
EV/EBITDA 11.94
EPS(TTM)2.45
EY3.45%
EPS(NY)4.54
Fwd EY6.39%
FCF(TTM)4.48
FCFY6.3%
OCF(TTM)5.29
OCFY7.44%
SpS27.63
BVpS14.99
TBVpS6.1
PEG (NY)0.34
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.39%
ROE -51.5%
ROCE 13.58%
ROIC 10.73%
ROICexc 14.43%
ROICexgc 23.98%
OM 14.78%
PM (TTM) N/A
GM 65.44%
FCFM 16.22%
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score6
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 2.81
Debt/EBITDA 1.49
Cap/Depr 36.16%
Cap/Sales 2.93%
Interest Coverage 7.78
Cash Conversion 83.7%
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.42
Altman-Z 2.7
F-Score6
WACC10.24%
ROIC/WACC1.05
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)181.61%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%514.29%
EPS Next Y85.5%
EPS Next 2Y44.89%
EPS Next 3Y33.17%
EPS Next 5Y23.52%
Revenue 1Y (TTM)-2.93%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%-1.6%
Revenue Next Year-0.75%
Revenue Next 2Y1.94%
Revenue Next 3Y3.41%
Revenue Next 5Y4.8%
EBIT growth 1Y1504.35%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year37.57%
EBIT Next 3Y18.78%
EBIT Next 5Y16.87%
FCF growth 1Y151.42%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y75.1%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%